You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Johnson and Johnson
Boehringer Ingelheim
AstraZeneca
Harvard Business School

Last Updated: May 16, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DELATESTRYL

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Delatestryl

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01017458 Safety and Tolerability of MK0773 in Healthy Older Men (0773-004) Completed Merck Sharp & Dohme Corp. Phase 1 2007-06-01 This study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of MK0773 in healthy older men.
NCT03516812 Testosterone Enanthate and Olaparib in Treating Participants With Castration-Resistant Prostate Cancer Recruiting National Cancer Institute (NCI) Phase 2 2018-08-29 This phase II trial studies how well testosterone enanthate and olaparib work in treating participants with prostate cancer that has progressed despite hormonal therapy. Hormonal therapy, such as leuprolide, may lessen the amount of male sex hormones made by the body. In patients that have developed progressive cancer in spite of standard hormonal treatment (i.e. castration-resistant prostate cancer), administering testosterone enanthate may result in regression of tumors by causing DNA damage in cancer cells that have adapted to low testosterone conditions. Olaparib may stop the growth of tumor cells by blocking some of the enzymes involved in repairing DNA damage. Therefore, giving testosterone enanthate and olaparib together may work better in treating castration-resistant prostate cancer by generating DNA damage that the cancer cell is unable to repair.
NCT03516812 Testosterone Enanthate and Olaparib in Treating Participants With Castration-Resistant Prostate Cancer Recruiting University of Washington Phase 2 2018-08-29 This phase II trial studies how well testosterone enanthate and olaparib work in treating participants with prostate cancer that has progressed despite hormonal therapy. Hormonal therapy, such as leuprolide, may lessen the amount of male sex hormones made by the body. In patients that have developed progressive cancer in spite of standard hormonal treatment (i.e. castration-resistant prostate cancer), administering testosterone enanthate may result in regression of tumors by causing DNA damage in cancer cells that have adapted to low testosterone conditions. Olaparib may stop the growth of tumor cells by blocking some of the enzymes involved in repairing DNA damage. Therefore, giving testosterone enanthate and olaparib together may work better in treating castration-resistant prostate cancer by generating DNA damage that the cancer cell is unable to repair.
NCT03716739 Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency Not yet recruiting National Institute on Aging (NIA) Phase 2 2019-01-01 The purpose of this phase II trial is to determine the efficacy and safety of testosterone replacement therapy (TRT) in improving the symptoms of androgen deficiency and health-related quality of life in men with prostate cancer who have undergone radical prostatectomy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Delatestryl

Condition Name

Condition Name for Delatestryl
Intervention Trials
Spinal Cord Trauma 1
Hormone Deficiency 1
Wounds and Injury 1
Prostate Adenocarcinoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Delatestryl
Intervention Trials
Prostatic Neoplasms 3
Endocrine System Diseases 1
Nervous System Diseases 1
Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Delatestryl

Trials by Country

Trials by Country for Delatestryl
Location Trials
United States 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Delatestryl
Location Trials
Florida 1
Maryland 1
Washington 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Delatestryl

Clinical Trial Phase

Clinical Trial Phase for Delatestryl
Clinical Trial Phase Trials
Phase 3 1
Phase 2 4
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Delatestryl
Clinical Trial Phase Trials
Not yet recruiting 4
Completed 1
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Delatestryl

Sponsor Name

Sponsor Name for Delatestryl
Sponsor Trials
United States Department of Defense 1
Brigham and Women's Hospital 1
North Florida Foundation for Research and Education 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Delatestryl
Sponsor Trials
Other 8
NIH 2
U.S. Fed 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Moodys
McKesson
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.